Lalla, Rajesh V. http://orcid.org/0000-0002-7662-6937
Solé, Sebastián
Becerra, Sergio
Carvajal, Claudia
Bettoli, Piero
Letelier, Hernán
Santini, Alejandro
Vargas, Lorena
Cifuentes, Alexander
Larsen, Francisco
Jara, Natalia
Oyarzún, Jorge
Feinn, Richard
Bustamante, Eva
Martínez, Benjamín
Rosenberg, David
Galván, Tomas
Funding for this research was provided by:
Ingalfarma, SpA
Article History
Received: 14 October 2019
Accepted: 12 February 2020
First Online: 8 April 2020
Compliance with ethical standards
: Local Ethics Committee approval was obtained at each site and all subjects provided written informed consent. All procedures performed in studies involving human subjects were in accordance with the ethical standards of the local institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: RVL has served as a paid consultant for Ingalfarma SpA, Colgate Oral Pharmaceuticals, Galera Therapeutics, Monopar Therapeutics, Mundipharma, and Sucampo Pharma; has received research support to his institution from Galera Therapeutics, Novartis, Oragenics, and Sucampo Pharma; and has received stock in Logic Biosciences. RF has served as a paid consultant for Ingalfarma SpA. DR and TG have a stock/ownership interest in Ingalfarma SpA. The remaining authors disclosed no conflicts.